Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Submit your nominations for the Fierce Innovation Awards - Entries close this Friday
mergers and acquisitions
Biotech
Lilly inks $2.88B Merida buyout to expand autoimmune pipeline
The deal will give Lilly a beachhead in efforts to treat autoimmune disease through the selective degradation of pathogenic autoantibodies.
Nick Paul Taylor
Aug 31, 2026 9:18am
BioMarin inks $275M Alesta buyout to challenge AstraZeneca
Aug 18, 2026 9:15am
Tarsus pays $450M for Alkeus and its ph. 3 retinal disease drug
Aug 6, 2026 10:30am
Curium strikes up to $8B deal for radiopharma rival Lantheus
Aug 3, 2026 2:20pm
Fierce Pharma
Editor’s Corner: Why an AZ-BMS merger would be a very bad idea
Aug 3, 2026 12:25am
BMS CEO doesn’t ‘feel any compulsion to chase deals’
Jul 30, 2026 10:37am
